Wallace Capital Management’s AbbVie ABBV Stock Holding History

Wallace Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$365K	Sell	1,676 -113	-6%	-$25.1K	0.04%	56
2025 Q4	$409K	Hold	1,789	–	–	0.05%	54
2025 Q3	$414K	Hold	1,789	–	–	0.05%	55
2025 Q2	$332K	Hold	1,789	–	–	0.05%	56
2025 Q1	$375K	Buy	1,789 +3	+0.2%	+$583	0.05%	58
2024 Q4	$317K	Hold	1,786	–	–	0.04%	59
2024 Q3	$353K	Buy	1,786 +573	+47%	+$107K	0.05%	63
2024 Q2	$208K	Buy	+1,213	New	+$201K	0.03%	72
2016 Q1	–	Sell	-4,106	Closed	-$243K	–	54
2015 Q4	$243K	Buy	+4,106	New	+$236K	0.05%	50
2015 Q3	–	Sell	-3,385	Closed	-$227K	–	54
2015 Q2	$227K	Buy	+3,385	New	+$221K	0.04%	53
2015 Q1	–	Sell	-3,381	Closed	-$221K	–	55
2014 Q4	$221K	Buy	+3,381	New	+$213K	0.04%	51

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wallace Capital Management's ABBV Position: Q1 2026 in Review

Wallace Capital Management reduced its AbbVie (ABBV) stake by 6.3% in Q1 2026, selling an estimated $25.1K and leaving 1,676 shares worth $365K. The position accounts for 0.04% of the portfolio, ranked #56.

Wallace Capital Management first reported a position in ABBV in Q4 2014 and has held it in 11 quarters since. The position peaked at $414K in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Wallace Capital Management held 1,676 shares of AbbVie worth $365K as of Q1 2026.
Wallace Capital Management sold 113 AbbVie shares in Q1 2026, an estimated $25.1K.
AbbVie made up 0.04% of Wallace Capital Management's portfolio in Q1 2026, its #56 holding.
Wallace Capital Management first reported a position in AbbVie in Q4 2014 and has held it in 11 quarters since.
Wallace Capital Management's AbbVie position peaked at $414K in Q3 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Wallace Capital Management's 13F filing for Q1 2026, filed 15 May 2026.